MedImmune is recalling 4.7 million doses of its intranasal H1N1 flu vaccine that lost potency after shipment. The recall is not related to safety problems, the FDA said, and the 13 batches "passed pre-release testing for safety, purity and potency." Sanofi-Aventis announced a similar recall last week for its H1N1 vaccine for children.

Related Summaries